Capillary device supports in-office blood collection in diverse practice locations without the need for venipuncture BOULDER, Colo. --(BUSINESS WIRE)--Nov. 14, 2023-- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today the validation

BOULDER, Colo. --(BUSINESS WIRE)--Nov. 9, 2023-- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton , Chief Executive Officer, will participate in two upcoming investor conferences: Canaccord Genuity Medtech, Diagnostics,

  Third quarter 2023 Lung Diagnostic test volume grew 60% over the comparable period in 2022 and 6% over second quarter of 2023; Third quarter 2023 gross profit margin of 76% versus 67% for the third quarter 2022 and 73% for the second quarter of 2023; Net loss, which includes certain non-cash

BOULDER, Colo. --(BUSINESS WIRE)--Oct. 24, 2023-- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus on lung disease, announced today that it will release financial results for the third quarter ended September 30, 2023 after the close of trading on Tuesday, November

Studies highlight the clinical utility and real-world impact of the Nodify CDT® and Nodify XL2® tests in managing both benign and malignant pulmonary nodules. BOULDER, Colo. --(BUSINESS WIRE)--Oct. 3, 2023-- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung

New data highlights two novel proteomic tests that support treatment decision making in patients with non-small cell lung cancer (NSCLC): Expanded analysis of the VeriStrat ® host immune classifier’s ability to predict immune checkpoint inhibition (ICI) response in patients with advanced stage

BOULDER, Colo. --(BUSINESS WIRE)--Sep. 5, 2023-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton , Chief Executive Officer of Biodesix , will participate in two upcoming investor conferences: Morgan Stanley

Data demonstrates a 51% relative increase in the proportion of lung nodule biopsies diagnosing cancer BOULDER, Colo. --(BUSINESS WIRE)--Aug. 22, 2023-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that a new analysis

Second quarter 2023 Core Lung Diagnostic revenue of $11.4 million increased 58% over the comparable period in 2022 and 33% over the first quarter of 2023; Second quarter 2023 gross profit margin of 73% versus 64% for the second quarter 2022 and 65% for the first quarter 2023; Revenue continues to

BOULDER, Colo. --(BUSINESS WIRE)--Aug. 1, 2023-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton , Chief Executive Officer of Biodesix , will present and host in-person 1x1 investor meetings at the